Polaris Group
Polaris Group develops pegargiminase (ADI-PEG 20), an enzyme that starves tumours lacking argininosuccinate synthetase of arginine, which improved survival in pleural mesothelioma in the phase 3 ATOMIC-Meso trial.
Overview
Polaris Group, based in San Diego with roots in Taiwan, develops ADI-PEG 20 (pegargiminase), a pegylated arginine deiminase that removes arginine from the blood. Tumours that have lost the enzyme argininosuccinate synthetase 1 (ASS1) cannot make their own arginine and are selectively starved; the approach was tested in liver cancer, melanoma and sarcoma before the phase 3 ATOMIC-Meso trial in non-epithelioid pleural mesothelioma reported longer survival with pegargiminase added to chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Scorecard
All companies- phase 3 +3
- modalities +2
- registry trials +10
Similar pages
not linked directly; found by shared links- TrialStudy of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Shares ADI-PEG20, Hepatocellular carcinoma.
- CompanyGC Cell
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyAscentawits Pharmaceuticals
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyImunon
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Mesothelioma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.